Skip to main content
60°
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Panbela Therapeutics Inc
(NQ:
PBLA
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Mar 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Panbela Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
PBLA Stock Earnings: Panbela Therapeutics Misses EPS for Q1 2024
May 15, 2024
PBLA stock results show that Panbela Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac
May 06, 2024
Developed in collaboration with Sanofi.
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
May 01, 2024
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Recap: Panbela Therapeutics Q4 Earnings
March 26, 2024
Via
Benzinga
Earnings Preview: Panbela Therapeutics
March 25, 2024
Via
Benzinga
Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week
April 30, 2024
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
April 22, 2024
Trial's lower-than-expected event rate suggests improved survival outcomes
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Panbela Announces Poster Presentation at American Association for Cancer Research:
April 18, 2024
Ivospemin/doxorubicin combination modulates polyamine metabolism to improve survival in murine ovarian cancer models
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Panbela Announces Transfer to OTCQB Market
April 16, 2024
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
PBLA Stock Earnings: Panbela Therapeutics Misses EPS for Q4 2023
March 26, 2024
PBLA stock results show that Panbela Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
Via
InvestorPlace
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
March 12, 2024
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Top 4 Health Care Stocks That Are Preparing To Pump This Month
February 23, 2024
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
February 15, 2024
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
February 14, 2024
Via
Benzinga
BioMedNewsBreaks – Panbela Therapeutics Inc. (NASDAQ: PBLA) Secures ~$9M in Public Offering
February 01, 2024
Via
Investor Brand Network
Panbela Announces Closing of Approximately $9.0 Million Public Offering
February 01, 2024
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
What's Going On With Panbela Therapeutics Stock Today?
January 30, 2024
Panbela Therapeutics announced acceptance of SBP-101 abstract for presentation and disclosed details of a public offering, expecting approximately $9.0 million in gross proceeds.
Via
Benzinga
Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
January 30, 2024
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
Crude Oil Down Over 1%; Science 37 Holdings Shares Spike Higher
January 29, 2024
U.S. stocks traded slightly higher toward the end of trading, with the Nasdaq Composite gaining around 75 points on Monday. The Dow traded up 0.03% to 38,121.11 while the NASDAQ rose 0.48% to...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Why Panbela Therapeutics Shares Are Trading Lower By 65%? Here Are Other Stocks Moving In Monday's Mid-Day Session
January 29, 2024
Shares of Panbela Therapeutics, Inc. (NASDAQ: PBLA) fell sharply during Monday’s session after the company announced pricing of a roughly $9 million public offering. Panbela Therapeutics shares dipped...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
January 29, 2024
Via
Benzinga
Dow Edges Lower; Cardlytics Shares Jump
January 29, 2024
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 20 points on Monday. The Dow traded down 0.04% to 38,093.41 while the NASDAQ rose 0.15% to 4,891.83. The S&P...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
US Stocks Edge Higher; Amazon And iRobot Agree To Terminate Acquisition Deal
January 29, 2024
U.S. stocks traded slightly higher this morning, with the Dow Jones index gaining around 25 points on Monday. Following the market opening Monday, The Dow traded up 0.07% to 38,134.80 while the NASDAQ...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Is Aclarion (ACON) Stock Down 16% Today?
January 29, 2024
Aclarion stock is falling on Monday after the company issued 500,000 shares of ACON to cover principal and accrued interest from notes.
Via
InvestorPlace
Why Is Panbela Therapeutics (PBLA) Stock Down 63% Today?
January 29, 2024
Panbela Therapeutics stock is falling on Monday after pricing a public offering for PBLA shares well below its price closing price.
Via
InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
January 29, 2024
Via
Benzinga
Why ZIM Integrated Shipping Services Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
January 29, 2024
ZIM Integrated Shipping Services Ltd. (NYSE: ZIM) shares rose sharply in today's pre-market trading after Jefferies upgraded the stock from Hold to Buy and raised its price target from $14 to $20.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
January 29, 2024
It's time to start the trading week with a dive into the biggest pre-market stock movers worth watching on Monday morning!
Via
InvestorPlace
Panbela Announces Pricing of Approximately $9.0 Million Public Offering
January 29, 2024
From
Panbela Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
January 26, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.